Kazia Therapeutics Limited (KZIA)
US Market

Kazia Therapeutics (KZIA) Income Statement


Kazia Therapeutics Income Statement

Last quarter (Q4 2023), Kazia Therapeutics's total revenue was AU$―, a decrease of ― from the same quarter last year. In Q4, Kazia Therapeutics's net income was AU$―. See Kazia Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Jun 23Jun 22Jun 21Jun 20Jun 19
Total Revenue
---AU$ 15.18MAU$ 0.00AU$ 0.00
Cost of Revenue
Gross Profit
---AU$ 15.18M--
Operating Expense
-AU$ 24.15MAU$ 24.76MAU$ 21.56MAU$ 12.19MAU$ 8.82M
Operating Income
-AU$ -24.15MAU$ -24.76MAU$ -21.56MAU$ -12.19MAU$ -8.82M
Net Non Operating Interest Income Expense
-AU$ 22.56KAU$ 2.00KAU$ 15.22MAU$ 66.00KAU$ 100.00K
Other Income Expense
-AU$ -3.39MAU$ 24.89MAU$ 10.99MAU$ -637.00KAU$ -1.85M
Pretax Income
-AU$ -20.74MAU$ -25.02MAU$ -8.91MAU$ -12.77MAU$ -10.57M
Tax Provision
-AU$ -271.09KAU$ -368.00KAU$ -484.00KAU$ -298.00KAU$ -298.00K
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
-AU$ -20.47MAU$ -73.90MAU$ -25.26MAU$ -12.47MAU$ -10.27M
Basic EPS
-AU$ -0.11AU$ -0.19AU$ -0.07--
Diluted EPS
-AU$ -0.11AU$ -0.19AU$ -0.07--
Basic Average Shares
-AU$ 184.28MAU$ 388.94MAU$ 360.91M--
Diluted Average Shares
-AU$ 184.28MAU$ 388.94MAU$ 360.91M--
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
-AU$ 24.15MAU$ 24.76MAU$ 21.56MAU$ 12.19MAU$ 8.82M
Net Income From Continuing And Discontinued Operation
-AU$ -20.47MAU$ -73.90MAU$ -25.26MAU$ -12.47MAU$ -10.27M
Normalized Income
----AU$ -11.84MAU$ -8.45M
Interest Expense
--AU$ -25.02MAU$ -8.91MAU$ -12.19MAU$ -8.82M
--AU$ -23.06MAU$ -7.64MAU$ -11.11MAU$ -7.74M
Currency in AUD

Kazia Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis